Metronomics Global Health Initiative

Dr Sidharth K TODARI

2020-06-26T10:59:22Z

Dr. Sidharth K Totadri completed his MD in pediatrics and DM in Pediatric Hematology Oncology from the Post Graduate Institute of Medical Research in Chandigarh, India. He further worked as a senior research associate there for 2.5 years after which he joined as an assistant Professor in the Pediatric Hematology Oncology unit of the Christian Medical College and Hospital, Vellore, India.

He manages children with benign hematological disorders such as hemolytic anemias and bleeding disorders, and malignancies including leukemias, lymphomas and solid tumors.

He was awarded the PODC scholarship and Fasanelli award for the best paper on bone sarcomas at the SIOP 2018 conference held in Tokyo, Japan.

DR Ramaswami KARTIK

2016-05-02T20:47:00Z

R. Kartik obtained first class honours BSc (1998) and MSc (2000) degree in Zoology from Sambalpur University, Orissa, India and obtained PhD (2007) in Zoology from National Botanical Research Institute (CSIR), Lucknow, Uttar Pradesh, India under the supervision of DR Ch. V .Rao and Dr S.P.Trivedi, from University of Lucknow where his research focus on development and screening of medicinal plants screening on hepatocellular carcinoma.
He then worked as application specialist in molecular biology for applied Biosystems for All-essa medical and scientific equipment Co based in Kuwait from 2006-2008. I offered a post-doctoral fellowship under Department of Biotechnology, Govt of India in 2009-10 where the focus of research in the area of tumor biology to study the role of EMT pathway in Oral squamous cell carcinoma.
I then a short stint as second post-doctoral in 2011 in Department of dermatology in Indian University school of medicine, Indianapolis, USA where the research focus on elucidating and validating of compound screening for development of drug for spinal muscular atropy.
He worked as a consultant (molecular biology) from June 2011- Feb 2012 for Food Tech International, Mangalore, India and joined as principal scientist for an oceanic edible international limited to head a laboratory for food testing (2012-14) and quality assurance and control.
He works as a consultant, biotechnology research for hydrocarbon solution private limited (2014-2015), and was involved in designing, execution, implementation of state of art laboratory projects, proposal on research in field of biotechnology, life sciences and food biotechnology. All the related to projects focus in promoting our channel partner company Agilent Technologies.

In 2016, he joined as Clinical programme management executive in HLL life care limited in R&D for the development programme on project related to women and child health care.

John EBOS

2015-04-01T10:57:00Z

John Ebos (PhD) is an Assistant Professor of Oncology in the Departments of Cancer Genetics and Medicine at Roswell Park Cancer Institute (RPCI), and is a member of the graduate faculty in the Department of Pharmacology and Therapeutics at the State University of New York at Buffalo.

Dr. Ebos completed his undergraduate training at McGill University and earned his PhD in the Department of Medical Biophysics at the University of Toronto under the mentorship of Dr. Robert S. Kerbel where he studied novel circulating molecules as potential surrogate markers of cancer progression and antiangiogenic drug efficacy.

Dr. Ebos doctoral studies led to the discovery of a soluble form of a key receptor for the vascular endothelial growth factor (VEGF) pathway, the ligand/receptor pairing that is the central target for all antiangiogenic therapies now FDA approved in several different cancer types. This soluble receptor (termed ‘sVEGFR-2'), along with several other circulating cytokines, were then studied as indicators of off-target ‘host' effects following therapy and investigated for their potential to facilitate disease progression.

Dr. Ebos' laboratory currently focuses on the molecular mechanisms that drive intrinsic and acquired drug resistance to stromal inhibitors in the treatment of spontaneous metastatic disease in mouse surgical models. This includes late-stage systemic metastasis as well as early-stage perioperative settings, such as with adjuvant and neoadjuvant treatment settings. The long-term goal of these efforts is to conduct preclinical models in conjunction with ongoing clinical trials so that benefits can be more readily predicted and rational designs for subsequent/alternative therapies can be developed.

Brendan BOOSTROM

2015-02-06T16:20:40Z

Dr. Brendan Boostrom is currently a resident in veterinary medical oncology and Master's student at the Colorado State University Flint Animal Cancer Center.

He received his B.S. in Animal Sciences from the University of Maryland, College Park, then his D.V.M from the University of California, Davis. During veterinary school, he pursued his passion for oncology, receiving outstanding student awards in both medical and radiation oncology. After a clinical internship at the University of Pennsylvania, he joined the Flint Animal Cancer Center in 2014.

Brendan's primary research interests are personalized cancer treatment, metronomic therapy, drug repositioning, and biomarker analysis.
Current projects includes a phase I clinical trial of dasatinib in tumor-bearing dogs, and growth inhibition of canine hemangiosarcoma by combining beta blockers and cytotoxic drugs.

Richard KAST

2015-02-03T08:08:09Z

Richard E. Kast MD is a clinical psychiatrist and academic cancer researcher.
He received an MD degree from the University of Copenhagen, Denmark, Faculty of Medicine and graduated from the psychiatry training program at the University of Burlington, Vermont, USA.
His 100+ oncology research papers have recently culminated in the CUSP9 treatment protocol, of which he is lead author. This metronomics protocol relies on the combinaition of several repositioned agents with metronomic temozolomide.

Paul FITZGERALD

2015-01-30T09:00:07Z

Paul J. Fitzgerald is a a behavioral neuroscientist in the United States. Paul has a Ph.D. in neuroscience from Johns Hopkins University, where he studied somatosensory cortex in the Steven Hsiao lab. After that,he was a neuroscience postdoc at the National Institutes of Health in the United States for four years, where he studied mouse models of mental illness in the Andrew Holmes lab.

Currently, He is a postdoctoral fellow at Texas A&M University, working in the learning and memory lab of Stephen Maren.

Paul has a general interest in neurotransmitter systems, especially norepinephrine and drugs that affect it. Since 2009 he has published a series of review articles suggesting that elevated norepinephrine signaling is a factor in causing a variety of diseases, including various types of cancer. He thinks that metronomic chemotherapy, in combination with norepinephrine transmission reducing drugs such as beta blockers, is an innovative approach to treating cancer that demands further scientific inquiry.

Barbara BILLER

2015-01-30T08:51:01Z

Pr Barbara Biller is currently Associate Professor of Oncology in the Dept. of Clinical Sciences, Colorado State University, USA

She got a B.A. in Biochemistry/Cell Biology at the University of California, San Diego
then D.V.M at the University of Wisconsin, Madison a MS in Clinical Veterinary Oncology from the University of Illinois, Urbana and a PhD in immunology from the Colorado State University.

She was the Secretary/Treasurer from the Veterinary Cancer Society from 2010 to 2013 and received the Veterinary Cancer Society Basic Science Research Award in 1997
and n Outstanding Oral Presentation award at the CVMBS Research Day, Colorado State University in 2007. Barbara is the author of over 15 publications.

As a veterinary oncologist, Barbara has extensive experience in conducting clinical trials, including study design and implementation, oversight of staff, patient care and data collection and analysis. The Animal Cancer Center at Colorado State University is highly regarded for its ability to perform translational research and conducts 15 to 25 externally funded clinical trials each year, comprising approximately 200 patients. In addition, our large oncology caseload (more than 1500 patients annually) assures rapid patient accrual. She has considerable expertise in the development of novel canine immunological assays and reagents, such as the identification of the canine regulatory T lymphocyte population using a flow cytometric assay.

Giuseppe CURIGLIANO

2014-09-08T16:08:00Z

Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work.

He is a clinician and researcher specializing in breast cancer.

Dr. Curigliano earned his MD at the Universita' Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection.

He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is assistant professor of Clinical Pharmacology at University of Milan.
In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumors,within a comprehensive cancer center accepting every year at least 85.000 first diagnosis atients. He practice in the in patient, out patient and day hospital setting. He served for 3 ears on emergency an palliative care section of the Division.

He is an active member of the merican Society of Clinical Oncology (ASCO), the European Society of Medical Oncology ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member f/and scientific coordinator for the International Cardio-Oncology Society (ICOS).
He serveson the Clinical Research Committee of the AIOM. He serves as faculty member in the uropean School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013 and served ad Chair of the metastatic breast cancer track for ESMO 2014 meeting in Madrid.

Dr. Curigliano's research experiences include principle or coinvestigator work in several
phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast
cancer. He has been also involved as principal investigator in several phase I studies with
peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting).

Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research
platform on new drug development in breast cancer at European Institute of Oncology. Dr.
Curigliano has written widely on oncology, including articles in the Journal of Clinical
Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed
article, most of them as first author) and several book chapters. He also reviews for a
number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the
Journal of the National Cancer Institute, the European Journal of Cancer and many other
“breast oriented journals”. He is member of the Editorial Board of Journal of Clinical
Oncology and Annals of Oncology. He serves in the press committee of the European Society of Medical Oncology as Spokesperson coordinator for breast cancer.

Martin VILLALBA GONZALEZ

2014-09-08T07:21:00Z

Martin Villalba Gonzalez is currently Directeur de Recherche and head of the team: immune system control of hematological neoplasias ( INSERM U1040) and
future member and head of the team: Lymphocytes differentiation, tolerance and metabolism: basis for immunotherapy at the Institute for Regenerative Medicine and Biotherapy (INSERM).

Martin trained in Madrid where he got a Ph.D. degree in Biological Sciences. He was then a post-dox in the Universita di Ferrara, in CNRS, and then in the LIAI (USA) from 4/97 to 10/99. He was then a Research Scientist at the LIAI for 2 additional years.

He is a reviewer for several journal inlcuding The Journal of Immunology, Experimental Cell Research, European Journal of Immunology, FEBS, PLOS one, Frontiers in Biosciences and Nature Medicine.
He is also a Grant Reviewer for the Alzheimer's Research trust and the MRC (United Kingdom), the Indo-French Center for the promotion of advanced research (IFCPAR) and the DFG (Deutsche Forschungsgemeinschaft).

During his carrer Martin has received several awards such as a Fellowship for postdoctoral studies at Universita di Ferrara, Italy, from M.E.C; a Fellowship for postdoctoral studies from Foundation pour la Recherche Medicale, a Special Fellowship of The Leukemia & Lymphoma Society “(formerly The Leukemia Society of America, Inc)”.

In 2009 he has been awarded the Prize of "chercheur d'avenir" (Languedoc-Rousillon)

Martin is the author or coauthor of 61 scietific articles.

Herman Andrés PERROUD

2013-12-04T09:02:54Z

Born and raised in a small town in Argentina, Herman Andrés Perroud obtained in 2009 his MD degree at the School of Medical Sciences, National University of Rosario (UNR), Argentina. In 2007, He obtained a Teaching Assistant position in Semiology and Methodology of Research in Medical Sciences, at the School of Medical Sciences, UNR. In 2009, after he gets his MD degree, He started working on his doctoral research project in metronomic chemotherapy for advanced breast cancer patients, under the direction of Dr. Graciela Scharovsky at the Experimental Oncology Section of the Institute of Experimental Genetics. Also in 2012 he completed two years of internship and post-grade of Internal Medicine at the Centennial´s Provincial Hospital in Rosario, Santa Fe. Presently, He is currently a resident in the Department of Medical Oncology at the Italian Hospital of Rosario.